Two novel structural classes of p38 kinase inhibitors

Abstract

Two patents claiming the use of structurally distinct p38 (mitogen-activated protein, MAP) kinase inhibitors are compared. One claims bisarylpyrazole derivatives and provides effective anti-inflammatory agents. The second claims the use of bisarylureas, which provide a novel non-azole template, as p38 inhibitors.

• cytokine synthesis inhibitor
• inflammation
• mitogen-activated protein kinase
• rheumatoid arthritis